Aridaman Pandit的动态

I'm helping our team at Virica Biotech share the mysteries of viral vectors with our new series! ?? Our small molecule enhancers integrate with any viral vector production platform (yes ANY). This versatility allows us to explore a diverse array of viral vectors and production processes within our lab, keeping me endlessly engaged and inspired. But with great diversity comes great complexity. We understand the challenges viral vector production can present. That's why we're looking to share our insights and expertise with you. All the wins and lessons we have learned in our journey. Do you have burning questions about viral vectors? Drop me a DM. #ViralVectors #Biotech #Biomanufacturing

?? We’re excited to introduce Keara, an associate scientist at Virica and host of our new Ask the Virologist series! ? Here’s a quick video to learn a little bit about her background and what we do here at Virica. ?? Leveraging our expert team and years of experience, we're excited to spark engaging scientific dialogue through our Ask the Virologist series. ?? DM us with feedback, questions or add to the discussion! Some questions we have recently received: Question from Ramon Mendoza: “What are the product-related and process-related impurities that impact transduction efficiency? Are there attributes one can measure which would help predict transduction efficiency in primary cells when titre is established in a different well established cell line?” A: This is a really interesting question! Some process impurities that may impact transduction efficiency: ? Contaminating cellular free DNA in the final product can activate the interferon pathway, reducing transduction efficiency. DOI:?10.3390/cells12050732. ? There are indications that variations in the vector membrane lipid profile can alter vector transducibility and function. Further, the producer cell used to generate the vectors may cause these variations. Therefore, membrane lipidomics may be an interesting metric. Here are a few papers to check out: **https://lnkd.in/dGpeCbUG. https://lnkd.in/d3k548a9?**https://lnkd.in/dWRT4s68 ? Presence of empty capsids or partially full capsids may necessitate higher quantities for effective transduction. Quantifying full/empty capsid ratios can be useful for addressing this. ? Specific glycoproteins used in transduction can impact efficiency; for instance, standard VSV-G may not be optimal for certain cell types like NK cells due to receptor expression differences. DOI:?10.3389/fimmu.2019.02873 Using model-cell lines for viral titer versus transducing primary cell lines: ? Using immortalized or cancer cell lines introduces genetic variations, potentially affecting sensitivity to impurities. For example defects in antiviral pathways in model cell lines may not reflect those in target cells, affecting transduction outcomes. ? Understanding the impurities and vector design implications above can help bridge the gap between model cell systems and target cells. DOI:?10.1016/j.cellsig.2005.10.008 Question from LAURA BELMAR “How do you do your payload analytics, and have you considered using mass photometry for in process quality assessment?”. A: Great question! This relates to some of the characteristics listed in the above question. Certainly full/empty ratios can be assessed in this way and is a technique that can work across all varieties of custom/standard viral serotypes! DOI:?10.3390/ijms241311033 #virology #AskaVirologist #biomanufacturing #cgtreads

Researchers have made significant advancements in gene editing, particularly with the development of a new CRISPR protein called enEbCas12a. This highly efficient and compact protein can be delivered into target cells using a safe virus like an adeno-associated virus (AAV), addressing the critical challenge of delivering gene-editing tools safely and effectively. Using advanced nuclear magnetic resonance spectroscopy, researchers at the Children's Hospital of Philadelphia have uncovered crucial steps in the CRISPR/Cas9 system, identifying a "surveillance" structure that controls DNA cutting to enhance precision. These discoveries pave the way for more accurate and safer gene-editing tools with profound implications for gene therapy and the biopharmaceutical industry. Enhanced CRISPR tools and a deeper understanding of CRISPR mechanisms can revolutionize gene-based treatments, including direct in-vivo therapies and improved cell therapies like CAR-T. For the biopharmaceutical sector, precise gene editing opens new possibilities for disease modeling and targeted therapy development, accelerating drug discovery and reducing costs. Companies like CRISPR Therapeutics are advancing therapies for genetic disorders such as sickle cell disease, demonstrating the real-world potential of this technology. As research progresses, gene therapy approaches are expected to become safer, more effective, and applicable to a wider range of genetic conditions, transforming patient care and ushering in a new era of personalized medicine. https://lnkd.in/gE3bfvp7 https://lnkd.in/gu8zBuqT #GeneTherapy #CRISPR #BiomedicalResearch #Pharmaceuticals #PrecisionMedicine #Biotechnology

Advanced Cell Diagnostics (ACD) a Spatial Bio-Techne brand sets a new standard in spatial biology with protease-free RNAscope multiomics. Optimized for same-slide detection of protein and RNA biomarkers with unparalleled sensitivity and tissue morphology, the newly developed RNAscope spatial multiomics workflow is compatible with both manual and automated assays and is incorporated in Bio-Techne’s recently announced best-in-class multiomics application on Lunaphore’s COMET platform. By eliminating the need for proteases often used in RNA detection, this advanced workflow preserves protein and RNA integrity and conserves tissue morphology. With this advancement, subcellular gene expression and multiomic changes can be easily quantified and image and data analysis are further simplified. Read the Press Release: https://bit.ly/3HyCwgK

On June 20th we are taking a deep dive into innovative #singlecell technologies, #learning how to manage challenging cell lines and finding optimum strategies for therapeutic targets. You are welcome to join our first #webinar!

RNA Horizons 2024 in Porto! https://rnahorizons.com/ I am super excited to present RNAble's recent data to RNA-therapeutics leaders. Building upon the groundbreaking developments of 2020, the symposium will convene a diverse array of experts, including RNA biologists, systems analysts, immunologists, and drug development specialists. Fostering a collaborative environment, this event will facilitate the exchange of cutting-edge research, the development of a unified scientific lexicon, and the acceleration of research and development efforts in RNA therapeutics. Key thematic areas of exploration will encompass: RNA system biology, including methods to sequence and identify RNA splicing, editing, and processing in health and disease. Expanding the scope of RNA therapeutics: RNA splicing and processing in health and disease. https://lnkd.in/d5p_FUfX

?? ?????? ????????-???????????????????? ????????????????????: ?????????????????????????????? ?????????????? ???????????????? ?????? ?????????????????? ???????????????? The RNA Next-Generation Sequencing (NGS) market is centered on advanced sequencing technologies for analyzing RNA to understand gene expression, mutations, and transcriptome profiling. It is widely used in research, diagnostics, and drug discovery, driving personalized medicine and advancements in oncology, immunology, and infectious diseases. Key Market Trends Increased Adoption in Oncology: RNA sequencing is crucial for understanding cancer biology and tailoring treatments. Growth of Transcriptomics: High demand for comprehensive RNA profiling in genomics research. Technological Advancements: Innovations in NGS platforms and data analytics boost adoption. ?????????? ???????? ???? ???????????????? ?????? ???????? ???????????? ????????????:?https://lnkd.in/g7v25eGf #Company | Roche | Illumina | Thermo Fisher Scientific | Beckman Coulter Diagnostics | Pacific Biosciences | Oxford Nanopore Technologies | Eurofins Scientific Finland Oy | Macrogen Europe | GENEWIZ | Berry Genomics | QIAGEN #Type Enrichment Approaches Amplicon-Based Approaches #Applications Research Institutes Hospitals and Clinics Biotechnology Company Diagnostic Lab ?????????? ????????, ???? ?????? ?????????????? ???????????? https://lnkd.in/dKh4YWp7 #Genomics #RNASequencing #PrecisionMedicine #NGS #Biotechnology #HealthcareInnovation #PersonalizedMedicine

2024 RNA Therapeutics Symposium Unlocking RNA's Potential in Medicine | September 25 – 27, 2024 | Alfandega Porto Congress Centre, Portugal #RNΑHorizons Are you interested in the latest advancements in RNA therapeutics? Join us at the RNA Horizons conference for stimulating discussions and presentations from leading experts in the field! Here's what you can expect: Explore key thematic areas in RNA system biology, including RNA splicing, editing, and processing for health and disease. Gain insights into the expanding scope of RNA therapeutics and its potential to revolutionize healthcare. Network and forge valuable connections with a diverse community of scientists and researchers. Shape the future trajectory of RNA-based therapies and their impact on human health. Don't miss this opportunity to be part of a groundbreaking event! Click here to learn more and register! https://rnahorizons.com #HCRI #RNA #Therapeutics #GeneEditing #Healthcare #Conferences #Science #Research

Celebrating scientific innovation in RNA therapies! With The Nobel Prize Prize?recently awarded for groundbreaking work on microRNA, we at baseclick are excited to share our contribution to this rapidly evolving field of RNA-targeted therapies. Our CEO, Dr. Thomas Frischmuth, recently co-authored the paper “Trimannose-coupled Antimir 21 for macrophage-targeted inhalation treatment of acute inflammatory lung damage”, published in Nature Communications (2023). This research highlights the potential of targeted therapies for inflammatory diseases, with a focus on selective targeting of macrophages. baseclick specializes in the development and production of modified oligos such as siRNA, ASO/LNA, gene editing and many more for treatment also of microRNA-associated diseases. Through our unique bioconjugation process, which utilizes click chemistry to attach e.g. trimannose for cell-specific targeting, we have successfully collaborated with renowned and one of the leading researcher in microRNA Professor Engelhardt from the Technische Universit?t München (Beck et al. 2023). We are proud to be at the forefront of this exciting research, producing these ground-breaking oligonucleotides for our customers and contributing to drive progress in RNA therapeutics. #RNAtherapeutics #microRNA #ClickChemistry #ASO #LNA #TargetedTherapy #Bioconjugation #baseclick #Inflammation #CellTargeting #PharmaInnovation #rnatics Trimannose-coupled antimiR-21 for macrophage-targeted inhalation treatment of acute inflammatory lung damage, C. Beck et al., 2023, Nature Communications, Vol. 14, 4564. https://lnkd.in/ecs9ZKB4